Cargando…

The molecular diversity of Luminal A breast tumors

Breast cancer is a collection of diseases with distinct molecular traits, prognosis, and therapeutic options. Luminal A breast cancer is the most heterogeneous, both molecularly and clinically. Using genomic data from over 1,000 Luminal A tumors from multiple studies, we analyzed the copy number and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciriello, Giovanni, Sinha, Rileen, Hoadley, Katherine A., Jacobsen, Anders S., Reva, Boris, Perou, Charles M., Sander, Chris, Schultz, Nikolaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2013
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824397/ https://www.ncbi.nlm.nih.gov/pubmed/24096568 http://dx.doi.org/10.1007/s10549-013-2699-3

Ejemplares similares

Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy
por: Pfefferle, Adam D., et al.
Publicado: (2015)

A pan-cancer survey of cell line tumor similarity by feature-weighted molecular profiles
por: Sinha, Rileen, et al.
Publicado: (2021)

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes
por: Prat, Aleix, et al.
Publicado: (2013)

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns
por: Bardowell, Sabrina A., et al.
Publicado: (2013)

Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse
por: Harrell, J. Chuck, et al.
Publicado: (2011)

Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes
por: Teinturier, Romain, et al.
Publicado: (2021)

Potential Tumor Suppressor Role for the c-Myb Oncogene in Luminal Breast Cancer
por: Thorner, Aaron R., et al.
Publicado: (2010)

Functional transcriptomic annotation and protein–protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer
por: Nuncia-Cantarero, Miriam, et al.
Publicado: (2018)

A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer
por: Hollern, Daniel P., et al.
Publicado: (2018)

Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer
por: Silva, Grace O., et al.
Publicado: (2015)

Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
por: Weigman, Victor J., et al.
Publicado: (2011)

Evaluating cell lines as tumour models by comparison of genomic profiles
por: Domcke, Silvia, et al.
Publicado: (2013)

Molecular characterization and heterogeneity of circulating tumor cells in breast cancer
por: Jakabova, Anna, et al.
Publicado: (2017)

Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study
por: Jinna, Nikita D., et al.
Publicado: (2023)

Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients
por: Engstrøm, M. J., et al.
Publicado: (2013)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women
por: Tseng, Ling-Ming, et al.
Publicado: (2017)

DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis
por: Valla, Marit, et al.
Publicado: (2021)

BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance
por: Kuilman, Midas M., et al.
Publicado: (2022)

No evidence for shedding of circulating tumor cells to the peripheral venous blood as a result of mammographic breast compression
por: Förnvik, Daniel, et al.
Publicado: (2013)

Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-α activity on breast metabolic signaling
por: Arnone, Alana A., et al.
Publicado: (2021)

FOXA1 is a determinant of drug resistance in breast cancer cells
por: Kumar, Uttom, et al.
Publicado: (2021)

Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients
por: Bingham, Catherine, et al.
Publicado: (2017)

Recurrent read-through fusion transcripts in breast cancer
por: Varley, Katherine E., et al.
Publicado: (2014)

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
por: Jank, Paul, et al.
Publicado: (2021)

Abstract 23 HLA-Homozygous iPSC from Cord Blood for the Generation of Cardiomyocytes for Allogeneic Cell Therapy to the Heart
por: Becker, Fabienne, et al.
Publicado: (2023)

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections
por: Muftah, Abir A., et al.
Publicado: (2017)

Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
por: Kusaczuk, Magdalena, et al.
Publicado: (2016)

Covid-19 related oncologist’s concerns about breast cancer treatment delays and physician well-being (the CROWN study)
por: Yao, Katharine A., et al.
Publicado: (2021)

The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivatives in human gastric cancer cells
por: Pawłowska, Natalia, et al.
Publicado: (2018)

Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells
por: Márquez, Marcela, et al.
Publicado: (2022)

Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer
por: Asaduzzaman, Muhammad, et al.
Publicado: (2017)

Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
por: Flocke, Lea S., et al.
Publicado: (2016)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention
por: Walter, Katherine R., et al.
Publicado: (2018)

Breast cancer research and treatment reconstruction of unilateral breast structure using three-dimensional ultrasound imaging to assess breast neoplasm
por: Lu, Yuanyuan, et al.
Publicado: (2019)

Association of reproductive history with breast tissue characteristics and receptor status in the normal breast
por: Gabrielson, Marike, et al.
Publicado: (2018)

Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients
por: Mast, Mirjam E., et al.
Publicado: (2014)

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
por: Lips, E. H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gheif86s8q2hggersb1oo8l939